



USAID
FROM THE AMERICAN PEOPLE

TB CARE I

TB CARE I - Botswana

**Year 2
Quarterly Report
April-June 2012**

July 30, 2012

Quarterly Overview

Reporting Country	Botswana
Lead Partner	KNCV
Collaborating Partners	-
Date Report Sent	
From	Obert Kachuwaire
To	Ms Joan LaRosa (USAID Director Botswana)
Reporting Period	April-June 2012

Technical Areas	% Completion
1. Universal and Early Access	75%
2. Laboratories	80%
Overall work plan completion	78%

Most Significant Achievements

TB CARE I provided technical input in collaboration with partners in the conducting of an LED Fluorescent Microscopy pilot workshop in May which trained 10 technicians (6 Female, 4 Male) and has supported the roll out and installation of iLED microscopes to 10 high workload smear microscopy sites.

The in-country technical advisor facilitated harmonization of TB/TBHIV training tools , conducted supervisory visits to 2 districts (14 facilities) to strengthen CTBC implementation and supported PPM policy framework finalization.

Through a core project mechanism with support from two KNCV consultants (Dr Valentina Anisimova and Dr Jerod Scholten), CDC Atlanta (Dr Tom Schninnick), a budget expert (Mr David Masengu) a second workshop supported the development of a draft TB specific laboratory strategic plan for Botswana and the development of a Strategic planning handbook for TB labs. The NRL will work towards finalization of the strategic plan and its endorsement by the MoH.

TB CARE I through a core project mechanism supported attendance of two senior staff (the NTP Manager and NTRL Technical Supervisor) to attend a Regional GeneXpert meeting in Kenya from the 21st-25th of May 2012 where the team developed a draft comprehensive Gene Xpert roll out plan.

Overall work plan implementation status

78%

Technical and administrative challenges

Lack of funding for per diem for NRL EQA staff to conduct site visits has resulted in delays in the conducting of site visits and follow-up of LED fluorescent microscopy implementing sites.

In-country Global Fund status and update

Botswana is awaiting funds from Global fund through the bridge funding mechanism which is still to be disbursed. TB CARE I has been supporting the Transitional Funding Mechanism proposal review phase through the in-country Senior Technical Advisor requested feedback on gaps in the proposal have been submitted to Global Fund.

Quarterly Technical Outcome Report

Technical Area		1. Universal and Early Access					Highlights of the Quarter	Challenges and Next Steps to Reach the Target
Expected Outcomes	Outcome Indicators	Baseline		Target		Result		
		Data	Year	Data	Year	Y1		
1.2 Increased quality of TB services delivered among all care providers (Supply)	1.2.4 CB-DOTS program is implemented Indicator Value: Score (0-3) based on definition.	2	2011	3	2014	2	In country Senior Technical advisor has facilitated harmonization of TB/TBHIV training tools, conducted supervisory visits to 2 districts (14 facilities), co-ordination of development of NTP annual performance plan 2012-2013, supported PPM policy framework, supported TFM proposal feedback.	The In-country Senior Technical Advisor will continue supporting the NTP in the roll out of the PPM package through training of private practitioners, and support visits to districts for monitoring of CTBC activities.

Technical Area		2. Laboratories					Highlights of the Quarter	Challenges and Next Steps to Reach the Target
Expected Outcomes	Outcome Indicators	Baseline		Target		Result		
		Data	Year	Data	Year	Y1		
2.1 Ensured capacity, availability and quality of laboratory testing in country needed to support the diagnosis and monitoring of TB patients	2.1.2 Laboratories with working internal and external quality assurance programs for tests that they provide including: a) smear microscopy, b) culture, c) DST, and d) rapid molecular test Indicator Value: Percent Numerator: Number of laboratories enrolled in EQA program meeting description above both nationwide and TB CARE areas. Denominator: All laboratories (national and TB CARE areas separately) that perform one or more of the above TB diagnostics.	100%	2011	100%	2012	100%	LED microscopy EQA program has been rolled out during the validation phase. Panel tests were prepared and sent to site. Blinded rechecking for light microscopy continues. Reports for the first quarter of 2012 were released with the 3 months reporting period.	Communication with SRL will be initiated to enroll NRL to FLD and LPA EQA. Panel test slides will be sent to sites rolling out LED microscope to assess implementers competency. Lack of funding for NRL EQA staff has delayed the follow-up site visits to support labs and to assess implementation of LED FM. Through the NTP and PEPFAR lab funds the EQA staff will be availed funding to continue activities.
	2.1.3 Accreditation of NTRL by SANAS Indicator Value: Yes/No Level: Central Source: TB CARE Means of Verification: Accreditation Certificate	No	2011	Yes	2012	Yes	Review of all QMS documents done.	NRL awaits surveillance assessment visit from SANAS in August.
2.3 Ensured optimal use of new approaches to the laboratory confirmation of TB and incorporation in national strategic lab plans	2.3.1 New technologies have been introduced Indicator Value: Number for each technique below by Central, Provincial, district and Peripheral levels 1. TB culture 2. First line DST 3. Second-line DST 4. HAIN MTBDRplus 5. GeneXpert 6. LED microscopy	0	2011	1-TB Culture/ central 1-First Line DST/ central 1-Sec Line DST/ Central 1-LED/ Central 9-LED/ District	2012	1 TB Culture/ central 1 First Line DST/ central 1 Second Line DST/ Central 1 LED/ Central 10 LED/District	LED microscopy introduced to 10 high volume laboratories in the country. All sites begin site validation of LED FM which is expected to be done by end of fourth quarter. Validation of FLD and DST continues. LPA validation is almost complete and awaits confirmatory results.	Validation reports for all sites to be compiled and a second workshop held for LED FM an additional site will begin LED FM. Regional Laboratory Consultant will visit the NRL to support finalization of the FLD, SLD and LPA assays.

Quarterly Activity Plan Report

1. Universal and Early Access			Activity	Approved Budget	Cumulative Completion	Planned Completion		Cumulative Progress and Deliverables up-to-date
Outcome	Activity #	Activity				Month	Year	
1.2 Increased quality of TB services delivered among all care providers (Supply)	1.1.1	Enhanced community DOTS implementation plan developed and rolled out	KNCV	18,882	 75%	Sep	2012	In country Senior Technical Advisor has been involved in the development of strategies and tools to scale up the implementation of community TB care: integration of community based HIV and TB care programs, harmonization of related tools, scale up of patient-centered-treatment (PCT) approach in selected districts. supervision visits to districts to strengthen DOTS implementation.

 75%

2. Laboratories			Activity	Approved Budget	Cumulative Completion	Planned Completion		Cumulative Progress and Deliverables up-to-date
Outcome	Activity #	Activity				Month	Year	
2.1 Ensured capacity, availability and quality of laboratory testing in country needed to support the diagnosis and monitoring of TB patients	2.1.1	Training of laboratory technicians to AFB smear microscopy and conducting external quality assurance through technical input into course and into EQA program	KNCV	10,263	 75%	Sep	2012	10 laboratory technicians (4 males, 6 females) were trained in LED microscopy at the NRL EQA Unit. A Validation package containing Protocols and forms has been shared with the labs to begin the instrument site specific validation.
	2.1.2	Acquire and maintain SANAS Accreditation of National TB Reference Laboratory through technical input into accreditation	KNCV	7,500	 100%	Sep	2012	Botswana NTRL has received its official accreditation certificate from the South Africa National Accreditation Systems(SANAS) after closing of identified gaps.
2.3 Ensured optimal use of new approaches to the laboratory confirmation of TB and incorporation in national strategic lab plans	2.3.1	Finalized validation of MGIT DST for 1st line drugs and begin validation for second line testing through bi-annual regional TA	KNCV	10,110	 65%	Sep	2012	Validation of FLD and SLD is in progress NRL staff have moved to the reproducibility phase of the validation. The Regional laboratory consultant from Kenya will provide TA to review current progress and to support finalization of the validation through the writing up of the validation reports.

 80%

Quarterly MDR-TB Report

Country	Botswana
----------------	-----------------

Period	APRIL-JUNE 2012
---------------	------------------------

MDR TB cases diagnosed and put on treatment in country

Quarter	Number of MDR cases diagnosed	Number of MDR cases put on treatment
Jan-Dec 2010	106	92
Jan-Sep 2011	30	0
Oct-Dec 2011	16	44
Total 2011	46	44
Jan-Mar 2012	21	18
Apr-Jun 2012	Not yet available	Not yet available
To date in 2012	#VALUE!	#VALUE!

Quarterly GeneXpert Report

Country	Botswana
---------	----------

Period	April-June 2012
--------	-----------------

Table 1: GeneXpert instruments and cartridges procured or planned by quarter with TB CARE I funds

	Procured			# still planned for procurement in APA 2	Month, Year procurement planned (i.e. April 2012)
	Jan-Dec 2011	Jan-Jun 2012	Cumulative total		
# GeneXpert Instruments	0		0	0	
# Cartridges	0		0	0	

Table 2: Cumulative List of GeneXpert Instruments Procured to Date or Planned in the Next Quarter (TB CARE I-funded)

Already procured or still planned? (i.e. Write "Procured" or "Planned")	Instrument	# of Modules (1, 2, 4, or 16)	Location(s) (facility name & city/ province or TBD)	USG Funding Source (e.g., PEPFAR COP FYxx, USAID) ¹	Partner/ Implementing Organization; Additional Comments
Procured	1				
	2				
	3				
	4				
	5				
	6				
	7				
	8				

¹ Differentiating between PEPFAR and USAID-funded is important. If it is PEPFAR funded, specify the fiscal year (i.e. FY2011). Add rows if there are more than 8 instruments in total.

Table 3: Cumulative Xpert MTB/RIF Cartridges Procured to Date or Planned for Next Quarter (TB CARE I-

Already procured or still planned? (i.e. Write "Procured" or "Planned")	Order #	# of Cartridges*	Location(s) (facility name and city/ province or TBD)	USG Funding Source (e.g., PEPFAR COP FYxx, USAID) ¹	Comments
Procured	1				
	2				
	3				
	4				
	5				

*There are 10 cartridges per kit, but we need the total # of **cartridges** (not kits)
Add an additional row for every procurement order of cartridges

Any additional information/clarifications to the above (optional)

Please provide a brief description of any significant problems encountered in use of the GeneXpert machine(s) and Xpert MTB/RIF cartridges

Please describe technical assistance or evaluation of implementation activities performed and planned.

Quarterly Photos (as well as tables, charts and other relevant materials)

Inventory List of Equipment - TB CARE I



TB CARE I

Organization:	TB CARE I
Country:	Botswana
Reporting period:	April-June 2012
Year:	APA 2

Description (1)	ID numbers (2)	Acquisition date (3)	Acquisition cost (4)	V.A.T (5)	Location (6)	Condition (7)	Disposition date (8)	Title held by (9)	Insurance Policy #
Lenovo laptop	L3-BHW4H 09/05	November 2009	\$845.00	125.76	Gaborone	New		KNCV	None
Lenovo laptop	L3-BHY0E 09/05	November 2009	\$845.00	125.76	Gaborone	New		KNCV	None
Canon i-Sensys Printer/sc	ELA09942	November 2009	\$150	22.50	Gaborone	New		KNCV	None
Dell-Inspiron laptop	14RQ4Q1	September 2011	\$985.00	147.75	Gaborone	New		KNCV	None
Toshiba- External hard dri	68571056AG	September 2011	\$76.76	11.51	Gaborone	New		KNCV	None

- (1) Description of equipment: transportation (vehicles), administration (computers, faxes), laboratory equipment or others
 (2) Identification number (eg Manufacturer's serial number, model number, Federal stock number, national stock number)
 (3) Date of invoice
 (4) Total price including any sales tax paid. Use currency on invoice
 (5) Note any sales tax charged
 (6) Address
 (7) Good/fair or bad
 (8)+(9) Ultimate disposition data, (in the case of a vehicle) including date of disposal and sales price or the method used to determine current fair market value.
 where a recipient compensated TB CARE I for its share. Attach supplementary info